Alumis Inc. (ALMS)
- Previous Close
11.97 - Open
12.13 - Bid 8.64 x 200
- Ask 14.57 x 200
- Day's Range
11.23 - 12.23 - 52 Week Range
10.37 - 13.53 - Volume
38,737 - Avg. Volume
216,363 - Market Cap (intraday)
620.198M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.48 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.33
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
www.alumis.comRecent News: ALMS
View More
Performance Overview: ALMS
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALMS
View MoreValuation Measures
Market Cap
651.48M
Enterprise Value
473.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-189.03M
Diluted EPS (ttm)
-3.48
Balance Sheet and Cash Flow
Total Cash (mrq)
209.53M
Total Debt/Equity (mrq)
15.75%
Levered Free Cash Flow (ttm)
--
Research Analysis: ALMS
View MoreCompany Insights: ALMS
ALMS does not have Company Insights